PURPOSE OF REVIEW: To inform readers on the ongoing activities of the Prostate cancer Research International: Active Surveillance (PRIAS) study in the light of current findings and research problems on active surveillance worldwide. RECENT FINDINGS: Recent data from the PRIAS study combined with PubMed-based literature from the last 3 years. SUMMARY: The PRIAS study is a rapidly growing registry for active surveillance of low-risk prostate cancer. The study is conducted worldwide, facilitated by an electronic Web-based decision tool with password-restricted access for physicians. Inclusion and monitoring is performed according to protocol. Over 2000 men have been included from over 100 participating centres in 17 countries in four continents. The study was initiated in December 2006. Risk reclassification on repeat biopsy during follow-up has occurred in 27% of biopsied men, although a switch towards active therapy has been performed in 22% of the total cohort.
PURPOSE OF REVIEW: To inform readers on the ongoing activities of the Prostate cancer Research International: Active Surveillance (PRIAS) study in the light of current findings and research problems on active surveillance worldwide. RECENT FINDINGS: Recent data from the PRIAS study combined with PubMed-based literature from the last 3 years. SUMMARY: The PRIAS study is a rapidly growing registry for active surveillance of low-risk prostate cancer. The study is conducted worldwide, facilitated by an electronic Web-based decision tool with password-restricted access for physicians. Inclusion and monitoring is performed according to protocol. Over 2000 men have been included from over 100 participating centres in 17 countries in four continents. The study was initiated in December 2006. Risk reclassification on repeat biopsy during follow-up has occurred in 27% of biopsied men, although a switch towards active therapy has been performed in 22% of the total cohort.
Authors: Hosam M Zowawi; Patrick N A Harris; Matthew J Roberts; Paul A Tambyah; Mark A Schembri; M Diletta Pezzani; Deborah A Williamson; David L Paterson Journal: Nat Rev Urol Date: 2015-09-01 Impact factor: 14.432
Authors: Vitor da Silva; Ilias Cagiannos; Luke T Lavallée; Ranjeeta Mallick; Kelsey Witiuk; Sonya Cnossen; James A Eastham; Dean A Fergusson; Chris Morash; Rodney H Breau Journal: Can Urol Assoc J Date: 2017-08 Impact factor: 1.862
Authors: Ottavio de Cobelli; Daniela Terracciano; Elena Tagliabue; Sara Raimondi; Danilo Bottero; Antonio Cioffi; Barbara Jereczek-Fossa; Giuseppe Petralia; Giovanni Cordima; Gilberto Laurino Almeida; Giuseppe Lucarelli; Carlo Buonerba; Deliu Victor Matei; Giuseppe Renne; Giuseppe Di Lorenzo; Matteo Ferro Journal: PLoS One Date: 2015-10-07 Impact factor: 3.240
Authors: Rasa Ruseckaite; Kerri Beckmann; Michael O'Callaghan; David Roder; Kim Moretti; Jeremy Millar; Sue Evans Journal: BMC Cancer Date: 2016-08-05 Impact factor: 4.430
Authors: Matteo Ferro; Giuseppe Lucarelli; Dario Bruzzese; Giuseppe Di Lorenzo; Sisto Perdonà; Riccardo Autorino; Francesco Cantiello; Roberto La Rocca; Gian Maria Busetto; Amelia Cimmino; Carlo Buonerba; Michele Battaglia; Rocco Damiano; Ottavio De Cobelli; Vincenzo Mirone; Daniela Terracciano Journal: Oncotarget Date: 2017-03-14